SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 61.59-3.8%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (7624)12/28/2002 4:56:14 PM
From: Harold Engstrom  Read Replies (2) of 52153
 
It is odd: the stock traded higher when there was real uncertainty about ODAC outcome. The outcome was extremely favorable to CRXA and the stock trades lower. I had thought that the market had already bet outcome would be negative.

The ODAC pretty much seemed to indicate that if they were NHL patients that they would place more faith in this that other treatments. $50MM does seem way too low. With GSK behind it I thought your $250MM estimate was reasonable.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News